Show simple item record

dc.contributor.authorFujihara, Kenji Mark
dc.date.accessioned2021-10-05T07:15:15Z
dc.date.available2021-10-05T07:15:15Z
dc.date.issued2021
dc.identifier.urihttp://hdl.handle.net/11343/286074
dc.description© 2021 Kenji Mark Fujihara
dc.description.abstractThe tumour suppressor gene TP53 is mutated in over half of all cancers, resulting in mutant p53 protein accumulation and poor patient survival. Decades after the discovery that p53 plays a central role in the human body’s defence against cancer, the development of effective therapeutic strategies to target mutant p53 cancers still remains an unmet need in oncology. Eprenetapopt (also known as APR-246 and PRIMA-1MET) is currently in clinical development as a mutant p53 reactivator. The reported mechanism of action of eprenetapopt is to restore wild-type p53 functionality to mutant p53 in cancer cells, triggering p53-dependent cell cycle arrest and caspase- dependent apoptosis. As a result, clinical investigation of eprenetapopt has focused on TP53-mutated cancers, relying solely on TP53 mutation status for patient selection into clinical trials. However, the mechanism of action of eprenetapopt remains contentious, as evidence demonstrates that eprenetapopt maintains strong potency in cancer cells with no mutant p53. Herein, utilising novel unbiased approaches, including CRISPR perturbation screening, metabolomics, proteomics and pan-cancer cellular-feature profiling, this thesis demonstrates two major innovations regarding the determinants of sensitivity and mechanisms of action of eprenetapopt. First, the expression of SLC7A11, which encodes the functional subunit of the cystine- glutamate antiporter, not TP53-mutation status, is the major determinant of sensitivity to eprenetapopt. Second, eprenetapopt triggers a caspase-independent, iron- dependent form of cell death known as ferroptosis, following glutathione depletion and inhibition of iron-sulfur cluster biogenesis. Together, this thesis provides a roadmap for broadening the clinical utility of eprenetapopt as a ferroptosis inducer in haematological and solid malignancies, beyond TP53-mutant cancers.
dc.rightsTerms and Conditions: Copyright in works deposited in Minerva Access is retained by the copyright owner. The work may not be altered without permission from the copyright owner. Readers may only download, print and save electronic copies of whole works for their own personal non-commercial use. Any use that exceeds these limits requires permission from the copyright owner. Attribution is essential when quoting or paraphrasing from these works.
dc.subjectCancer therapeutics
dc.subjectCancer metabolism
dc.subjectEprenetapopt
dc.subjectAPR-246
dc.subjectPRIMA-1MET
dc.subjectSLC7A11
dc.subjectFerroptosis
dc.subjectIron-sulfur cluster biogenesis
dc.subjectNFS1
dc.titleThe determinants of sensitivity and mechanism of action of eprenetapopt (APR-246)
dc.typePhD thesis
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.thesis.supervisornameNicholas Clemons
melbourne.contributor.authorFujihara, Kenji Mark
melbourne.thesis.supervisorothernameWayne Phillips
melbourne.thesis.supervisorothernameSusan Haupt
melbourne.tes.fieldofresearch1321101 Cancer cell biology
melbourne.tes.fieldofresearch2321108 Molecular targets
melbourne.tes.fieldofresearch3321104 Cancer therapy (excl. chemotherapy and radiation therapy)
melbourne.tes.fieldofresearch4310103 Cell metabolism
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record